Advertisement

CIGB-814, an altered peptide ligand derived from human heat-shock protein 60, decreases anti-cyclic citrullinated peptides antibodies in patients with rheumatoid arthritis

  • Oreste Corrales
  • Laura Hernández
  • Dinorah Prada
  • Jorge Gómez
  • Yusimy Reyes
  • Ana Marta López
  • Luis Javier González
  • Maria del Carmen Domínguez Horta
Brief Report
  • 29 Downloads

Abstract

Rheumatoid arthritis (RA) is a chronic T cell-mediated autoimmune disease. Serum autoantibodies against cyclic citrullinated peptides (anti-CCP) are significant markers for diagnosis and prognosis of this disease. Induction of immune tolerance as therapeutic approach for RA constitutes a current research focal point. In this sense, we carried out a phase I clinical trial in RA patients with a new therapeutic candidate (called CIGB-814); which induced mechanisms associated with restoration of peripheral tolerance in preclinical studies. CIGB 814 is an altered peptide ligand (APL), derived from a CD4+ T cell epitope of human heat-shock protein 60 (HSP60), an autoantigen involved in the pathogenesis of RA. Twenty patients with moderate disease activity were included in this open label trial. Sequential dose-escalation of 1, 2.5 and 5 mg of CIGB-814 was studied. Consecutive groups of six, five, and nine patients received a subcutaneous dose weekly of the peptide during the first month and one dose monthly during the next 5 months. The peptide was well tolerated and reduced disease activity. Here, we reported the quantification of anti-CCP antibodies during the treatment with this APL and in the follow-up stage. Anti-CCP antibodies were quantified in the plasma from patients by a commercial enzyme immunoassay at baseline (T0) and at weeks 28 and 48. Results showed that CIGB-814 induced a significant reduction of anti-CCP antibodies. In addition, this decrease correlated with clinical improvement in patients assessed by Disease Activity Score in 28 joints (DAS28) criteria. These findings reinforce the therapeutic potential of CIGB-814.

Keywords

Anti-CCP APL CIGB-814 HSP60 Rheumatoid arthritis 

Notes

Acknowledgements

We thank the patients who participated in this study.

Funding information

Study sponsorship was provided by CIGB and Ministry of Public Health of Cuba.

Compliance with ethical standards

Disclosures

None.

Ethical approval

The Ethics and Scientifics Committees at each study site approved the protocol: National Reference Center for Rheumatic Disease, Center for Genetic Engineering and Biotechnology, and Cuban Regulatory Authority (reference number 05-017-12-B).

Informed consent

All subjects provided theirs written informed consent. Patients were recruited from the National Reference Center for Rheumatic Diseases, Havana. This clinical trial was registered under number RPCEC00000238 at the Cuban Registry of Clinical Trials (www.registroclinico.sld.cu).

References

  1. 1.
    Myew-Ling T, Pierre M (2007) The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol 19:284–288CrossRefGoogle Scholar
  2. 2.
    Shrivastava AK, Pandey A (2013) Inflammation and rheumatoid arthritis. J Physiol Biochem 69:335–347CrossRefGoogle Scholar
  3. 3.
    Konig MF, Andrade F (2016) A critical reappraisal of neutrophil extracellular traps and NETosis mimics based on differential requirements for protein citrullination. Front Immunol 7:461PubMedPubMedCentralGoogle Scholar
  4. 4.
    Rubbert-Roth A (2012) Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology 51:38–47CrossRefGoogle Scholar
  5. 5.
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37CrossRefGoogle Scholar
  6. 6.
    Modi S, Soejima M, Levesque MC (2013) The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol 173:8–17CrossRefGoogle Scholar
  7. 7.
    Bacquet-Deschryver H, Jouen F, Quillard M, Ménard JF, Goëb V, Lequerré T, Mejjad O, Daragon A, Tron F, le Loët X, Vittecoq O (2008) Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol 28:445–455CrossRefGoogle Scholar
  8. 8.
    Genovese MC, Kaine JL, Lowenstein MB, Giudice JD, Baldassare A, Schechtman J, Fudman E, Kohen M, Gujrathi S, Trapp RG, Sweiss NJ, Spaniolo G, Dummer W, ACTION Study Group (2008) Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized,blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 58:2652–2661CrossRefGoogle Scholar
  9. 9.
    Wunderlich C, Oliviera I, Figueiredo CP, Rech J, Schett G (2017) Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-a longitudinal analysis. Semin Arthritis Rheum 46(6):709–714CrossRefGoogle Scholar
  10. 10.
    Zhao J, Li R, He J, Shi J, Long L, Li Z (2008) Mucosal administration of an altered CII263-272 peptide inhibits collagen-induced arthritis by suppression of Th1/Th17 cells and expansion of regulatory T cells. Rheumatol Int 29:9–16CrossRefGoogle Scholar
  11. 11.
    Katsara M, Deraos G, Tselios T, Matsoukas J, Apostolopoulos V (2008) Design of novel cyclic altered peptide ligands of myelin basic protein MBP83-99 that modulate immune responses in SJL/J mice. J Med Chem 51:3971–3978CrossRefGoogle Scholar
  12. 12.
    Kim EY, Durai M, Mia Y, Kim HR, Moudgil KD (2016) Modulation of adjuvant arthritis by cellular and humoral immunity to Hsp65. Front Immunol 7:203PubMedPubMedCentralGoogle Scholar
  13. 13.
    Zonneveld-Huijssoon E, Albani S, Prakken BJ, van Wijk F (2013) Heat shock protein bystander antigens for peptide immunotherapy in autoimmune disease. Clin Exp Immunol 171(1):20–29CrossRefGoogle Scholar
  14. 14.
    Domínguez MC, Lorenzo N, Barberá A et al (2011) An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic response in an animal model of adjuvant induced arthritis. Autoimmunity 44:471–482CrossRefGoogle Scholar
  15. 15.
    Barberá A, Lorenzo N, van Kooten P, van Roon J, de Jager W, Prada D, Gómez J, Padrón G, van Eden W, Broere F, del Carmen Domínguez M (2016) APL1, an altered peptide ligand derived from human heat-shock protein 60, increases the frequency of Tregs and its suppressive capacity against antigen responding effector CD4+T cells from rheumatoid arthritis patients. Cell Stress Chaperones 21:735–744CrossRefGoogle Scholar
  16. 16.
    Lorenzo N, Altruda F, Silengo L, Dominguez MC (2017) APL-1, an altered peptide ligand derived from heat-shock protein, alone or combined with methotrexate attenuates murine collagen induced arthritis. Clin Exp Med 17:209–216CrossRefGoogle Scholar
  17. 17.
    Cabrales-Rico A, Ramos Y, Besada V, del Carmen Domínguez M, Lorenzo N, García O, Alexis J, Prada D, Reyes Y, López AM, Masforrol Y, Garay H, González LJ (2017) Development and validation of a bioanalytical method based on LC–MS/MS analysis for the quantitation of CIGB-814 peptide in plasma from rheumatoid arthritis patients. J Pharm Biomed Anal 143:130–140CrossRefGoogle Scholar
  18. 18.
    Prada D, Gómez J, Lorenzo N et al (2018) Phase I clinical trial with a novel altered peptide ligand derived from human heat-shock protein 60 for treatment of rheumatoid arthritis: safety, pharmacokinetics and preliminary therapeutic effects. J Clin Trials 8:339.  https://doi.org/10.4172/2167-0870.1000339 CrossRefGoogle Scholar
  19. 19.
    Schneider M, Kruger K (2013) Rheumatoid arthritis –early diagnosis and disease management. Deutsches Arzteblatt Int 110(27–28):477–484Google Scholar
  20. 20.
    Wang P, Zheng SG (2013) Regulatory T cells and B cells: implication on autoimmune diseases. Int J Clin Exp Pathol 6:2668–2674PubMedPubMedCentralGoogle Scholar
  21. 21.
    Osterloh A, Geisinger F, Piédavent M, Fleischer B, Brattig N, Breloer M (2009) Heat shock protein 60 (HSP60) stimulates neutrophil effector functions. J Leukoc Biol 86:423–434CrossRefGoogle Scholar
  22. 22.
    Dapunt U, Gaida MM, Meyle E, Prior B, Hänsch GM (2016) Activation of phagocytic cells by Staphylococcus epidermidis biofilms: effects of extracellular matrix proteins and the bacterial stress protein GroEL on netosis and MRP-14 release. Pathog Dis 74(5):ftw035CrossRefGoogle Scholar
  23. 23.
    Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A (2013) NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 5(178):178ra40CrossRefGoogle Scholar
  24. 24.
    Maddur MS, Miossec P, Kaveri SV, Bayry J (2012) Th17 cells: biology pathogenesis of autoimmune, inflammatory diseases and therapeutic strategies. Am J Pathol 181:8–18CrossRefGoogle Scholar
  25. 25.
    Montesinos MC, Takedachi M, Thompson LF (2007) The anti-inflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5′-nucleotidase: findings in a study of ecto-5′-nucleotidase gene-deficient mice. Arthritis Rheum 56:1440–1445CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  • Oreste Corrales
    • 1
  • Laura Hernández
    • 1
  • Dinorah Prada
    • 2
  • Jorge Gómez
    • 2
  • Yusimy Reyes
    • 2
  • Ana Marta López
    • 2
  • Luis Javier González
    • 1
  • Maria del Carmen Domínguez Horta
    • 1
  1. 1.Center for Genetic Engineering and Biotechnology (CIGB)HavanaCuba
  2. 2.National Reference Center for Rheumatic Disease10 de Octubre HospitalHavanaCuba

Personalised recommendations